ADDvise Group AB (publ) (ADDV-A.ST)
SEK 11.2
(1.36%)
SEK 11.2
(1.36%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 411.9 Million SEK | 122.42% |
| 2022 | 203.79 Million SEK | 208.93% |
| 2021 | 55.81 Million SEK | 37.87% |
| 2020 | 42.64 Million SEK | 57.39% |
| 2019 | 27.96 Million SEK | 80.86% |
| 2018 | 15.33 Million SEK | 99.15% |
| 2017 | 12.23 Million SEK | -53.45% |
| 2016 | 18.37 Million SEK | 324.98% |
| 2015 | 4.62 Million SEK | -36.27% |
| 2014 | 7.27 Million SEK | 15.3% |
| 2013 | 5.17 Million SEK | 304.93% |
| 2012 | 1.27 Million SEK | 129.03% |
| 2011 | 558 Thousand SEK | 114.18% |
| 2010 | -3.93 Million SEK | 0.0% |
| 2009 | - SEK | -100.0% |
| 2008 | -532 Thousand SEK | -75.92% |
| 2007 | 1.48 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 84 Million SEK | -21.57% |
| 2024 Q2 | 80.6 Million SEK | -11.9% |
| 2024 Q3 | 88.3 Million SEK | 19.32% |
| 2023 Q2 | 121.6 Million SEK | 44.42% |
| 2023 Q3 | 93.5 Million SEK | -23.11% |
| 2023 FY | - SEK | 122.42% |
| 2023 Q4 | 107.1 Million SEK | 14.55% |
| 2023 Q1 | 84.2 Million SEK | -3.14% |
| 2022 FY | - SEK | 208.93% |
| 2022 Q1 | 21.22 Million SEK | 1.59% |
| 2022 Q2 | 34.3 Million SEK | 61.6% |
| 2022 Q3 | 39.17 Million SEK | 14.21% |
| 2022 Q4 | 86.93 Million SEK | 121.89% |
| 2021 FY | - SEK | 37.87% |
| 2021 Q1 | 8.86 Million SEK | -25.92% |
| 2021 Q2 | 15.76 Million SEK | 77.9% |
| 2021 Q3 | 13.27 Million SEK | -15.82% |
| 2021 Q4 | 20.89 Million SEK | 57.43% |
| 2020 FY | - SEK | 57.39% |
| 2020 Q2 | 15.13 Million SEK | 181.16% |
| 2020 Q1 | 5.38 Million SEK | -16.05% |
| 2020 Q4 | 11.96 Million SEK | 26.84% |
| 2020 Q3 | 9.43 Million SEK | -37.68% |
| 2019 Q3 | 6.66 Million SEK | -8.61% |
| 2019 FY | - SEK | 80.86% |
| 2019 Q1 | 7.1 Million SEK | 34.16% |
| 2019 Q2 | 7.29 Million SEK | 2.57% |
| 2019 Q4 | 6.41 Million SEK | -3.78% |
| 2018 Q2 | 4.05 Million SEK | -3.24% |
| 2018 Q4 | 5.29 Million SEK | 215.6% |
| 2018 FY | - SEK | 99.15% |
| 2018 Q1 | 4.19 Million SEK | 222.75% |
| 2018 Q3 | 1.67 Million SEK | -58.61% |
| 2017 Q2 | 5.55 Million SEK | 38.21% |
| 2017 FY | - SEK | -53.45% |
| 2017 Q4 | -3.41 Million SEK | -383.72% |
| 2017 Q3 | 1.2 Million SEK | -78.34% |
| 2017 Q1 | 4.02 Million SEK | 41.67% |
| 2016 FY | - SEK | 324.98% |
| 2016 Q3 | 4.77 Million SEK | -53.11% |
| 2016 Q4 | 2.83 Million SEK | -40.59% |
| 2016 Q2 | 10.19 Million SEK | 719.95% |
| 2016 Q1 | -1.64 Million SEK | 62.81% |
| 2015 FY | - SEK | -36.27% |
| 2015 Q1 | 5.48 Million SEK | 167.23% |
| 2015 Q2 | 3.91 Million SEK | -28.64% |
| 2015 Q3 | -2.04 Million SEK | -152.28% |
| 2015 Q4 | -4.42 Million SEK | -115.82% |
| 2014 Q4 | 2.05 Million SEK | 3212.9% |
| 2014 Q1 | 2.78 Million SEK | 0.72% |
| 2014 Q2 | 2.36 Million SEK | -15.07% |
| 2014 Q3 | 62 Thousand SEK | -97.38% |
| 2014 FY | - SEK | 15.3% |
| 2013 Q4 | 2.76 Million SEK | 202.07% |
| 2013 FY | - SEK | 304.93% |
| 2013 Q1 | -376 Thousand SEK | -128.53% |
| 2013 Q2 | 1.89 Million SEK | 602.66% |
| 2013 Q3 | 916 Thousand SEK | -51.53% |
| 2012 Q3 | -372 Thousand SEK | -140.04% |
| 2012 Q1 | -567 Thousand SEK | -221.67% |
| 2012 Q2 | 929 Thousand SEK | 263.84% |
| 2012 Q4 | 1.31 Million SEK | 454.3% |
| 2012 FY | - SEK | 129.03% |
| 2011 FY | - SEK | 114.18% |
| 2011 Q3 | 204 Thousand SEK | -74.31% |
| 2011 Q4 | 466 Thousand SEK | 128.43% |
| 2011 Q1 | -906 Thousand SEK | -550.75% |
| 2011 Q2 | 794 Thousand SEK | 187.64% |
| 2010 FY | - SEK | 0.0% |
| 2010 Q4 | 201 Thousand SEK | 111.56% |
| 2010 Q3 | -1.73 Million SEK | -61.02% |
| 2010 Q2 | -1.08 Million SEK | 18.0% |
| 2010 Q1 | -1.31 Million SEK | 0.0% |
| 2009 Q4 | - SEK | 0.0% |
| 2009 FY | - SEK | -100.0% |
| 2009 Q2 | 334 Thousand SEK | 173.09% |
| 2009 Q1 | -457 Thousand SEK | -96.14% |
| 2009 Q3 | - SEK | -100.0% |
| 2008 FY | - SEK | -75.92% |
| 2008 Q1 | 522 Thousand SEK | 24.58% |
| 2008 Q2 | 128 Thousand SEK | -75.48% |
| 2008 Q4 | -233 Thousand SEK | 0.0% |
| 2007 Q4 | 419 Thousand SEK | 0.0% |
| 2007 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acarix AB (publ) | -77.12 Million SEK | 634.089% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 0.0% |
| Arcoma AB | 6.24 Million SEK | -6492.51% |
| Bactiguard Holding AB (publ) | -89.98 Million SEK | 557.758% |
| BICO Group AB (publ) | 322.3 Million SEK | -27.8% |
| Boule Diagnostics AB (publ) | 65.97 Million SEK | -524.29% |
| CellaVision AB (publ) | 207.24 Million SEK | -98.75% |
| Clinical Laserthermia Systems AB (publ) | -68.4 Million SEK | 702.14% |
| Chordate Medical Holding AB (publ) | -27.94 Million SEK | 1574.072% |
| C-Rad AB (publ) | 48.9 Million SEK | -742.262% |
| Duearity AB (publ) | -24.77 Million SEK | 1762.295% |
| Dignitana AB (publ) | -264 Thousand SEK | 156122.727% |
| Episurf Medical AB (publ) | -87.7 Million SEK | 569.669% |
| Getinge AB (publ) | 5.92 Billion SEK | 93.053% |
| Scandinavian Real Heart AB (Publ) | -67.25 Million SEK | 712.49% |
| Iconovo AB (publ) | -35.33 Million SEK | 1265.684% |
| Integrum AB (publ) | 8.76 Million SEK | -4601.234% |
| Luxbright AB (publ) | -23.86 Million SEK | 1825.833% |
| Mentice AB (publ) | 28.87 Million SEK | -1326.592% |
| OssDsign AB (publ) | -122.02 Million SEK | 437.565% |
| Paxman AB (publ) | 31.22 Million SEK | -1218.966% |
| Promimic AB (publ) | -3.68 Million SEK | 11280.785% |
| Qlife Holding AB (publ) | -150.5 Million SEK | 373.679% |
| SciBase Holding AB (publ) | -51.82 Million SEK | 894.729% |
| ScandiDos AB (publ) | -13.35 Million SEK | 3184.007% |
| Sectra AB (publ) | 615.06 Million SEK | 33.031% |
| Sedana Medical AB (publ) | -51.67 Million SEK | 897.113% |
| Senzime AB (publ) | -118.82 Million SEK | 446.65% |
| SpectraCure AB (publ) | -20.96 Million SEK | 2064.328% |
| Stille AB | 56.04 Million SEK | -634.998% |
| Vitrolife AB (publ) | -3.18 Billion SEK | 112.932% |
| Xvivo Perfusion AB (publ) | 126.57 Million SEK | -225.422% |